UNCY

Unicycive Therapeutics Inc

• NASDAQ·4d ago

  Unicycive Therapeutics (UNCY) Loses 21.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

• PR Newswire·10/08 17:10

  Unicycive Therapeutics, Inc. (UNCY) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

• Dow Jones·10/01 11:05

  Press Release: Unicycive Therapeutics Appoints Meredith Manning to Board of Directors

• Dow Jones·09/29 15:49

  Unicycive Therapeutics Is Maintained at Buy by HC Wainwright & Co.

• Dow Jones·09/29 15:49

  Unicycive Therapeutics Price Target Cut to $13.00/Share From $15.00 by HC Wainwright & Co.

• Benzinga·09/29 15:40

  HC Wainwright & Co. Maintains Buy on Unicycive Therapeutics, Lowers Price Target to $13

• TipRanks·09/29 15:40

  Analysts’ Top Healthcare Picks: Vertex Pharmaceuticals (VRTX), Unicycive Therapeutics (UNCY)

• TipRanks·09/29 15:30

  Unicycive Therapeutics price target lowered to $13 from $15 at H.C. Wainwright

• NASDAQ·09/29 13:42

  Unicycive Resubmits OLC NDA With New Manufacturing Data To Support FDA Review; Stock Down

• NASDAQ·09/29 13:04

  Unicycive Therapeutics Resubmits Oxylanthanum Carbonate NDA To FDA

• TipRanks·09/29 12:19

  Unicycive Resubmits NDA for Kidney Disease Treatment

• TipRanks·09/29 11:15

  Unicycive Therapeutics announces resubmission of NDA for OLC

• Benzinga·09/29 11:07

  Unicycive Therapeutics Resubmits Its FDA New Drug Application For Oxylanthanum Carbonate For The Treatment Of Hyperphosphatemia In Patients With Chronic Kidney Disease On Dialysis; Expects PDUFA Date Six Months From Resubmission Date

• TipRanks·09/28 21:02

  Unicycive Faces New Securities Class Action Over NDA Disclosures

• Benzinga·09/28 20:37

  Unicycive Says Suit Alleges Securities Law Violations Over Statements On Oxylanthanum Carbonate FDA Application